Have a personal or library account? Click to login
SARS-CoV-2, SARS and MERS: Three formidable coronaviruses which have originated from bats Cover

SARS-CoV-2, SARS and MERS: Three formidable coronaviruses which have originated from bats

Open Access
|Feb 2021

Figures & Tables

Fig. 1

History of SARS-CoV (a), MERS-CoV (b), and COVID-19 epidemic consequence
History of SARS-CoV (a), MERS-CoV (b), and COVID-19 epidemic consequence

Fig. 2

Genomic comparison among SARS-CoV, MERS-CoV, and SARS-CoV-2. A schematic of the complete genome of SARS-CoV-2 (a), SARS-CoV (b), and MERS-CoV (c) are shown
Genomic comparison among SARS-CoV, MERS-CoV, and SARS-CoV-2. A schematic of the complete genome of SARS-CoV-2 (a), SARS-CoV (b), and MERS-CoV (c) are shown

Fig. 3

Distribution of SARS-CoV-2 in the world
Distribution of SARS-CoV-2 in the world

Comparison among SARS-CoV, MERS-CoV and SARS-CoV-2 in respect to their virology, epidemiology, and clinical manifestation

MERS-CoVSARS-CoVSARS-CoV-2
VirologyBetacoronavirus lineage 2CBetacoronavirus lineage 2BBetacoronavirus lineage B
ReceptorhDPP4ACE2Angiotensin-converting enzyme 2 (ACE2)
Genome Size30.1kb27.9kb29.9kb
SourceEvolutionary origin: bats Intermediate host: Not yet confirmed camel is the likely host LimitedEvolutionary origin: horseshoe bats Intermediate host: palm civets, raccoon dogs, and Chinese ferret badgerEvolutionary origin: horseshoe bat Intermediate host: Pangolin, cats
EpidemiologyZoonotic, human to human transmission, the disease is mostly localized in the Middle East, Eastern Africa, and Northern AfricaHuman to human transmission is well-recognized, affected many countriesHuman-to-human transmission respiratory droplets is the major route of transmission, fecal-oral route of transmission is considered but unconfirmed, Vertical transmission
Respiratory failureMore commonLess commonMore common
Travel associationLimited travel-associated exposureRecognized travel-associated exposureRecognized travel-associated exposure
Incubation period0–16 days2–8 days4–8 days
Male to Female Ratio3.3:11:1.32.7:1
Clinical presentationUnpredictable and erratic clinical course ranging from asymptomatic illness to severe pneumoniaA typical biphasic clinical courseFever, dry cough, and shortness of breath, and most patients (80%) experienced mild illness.
Laboratory FeaturesLeukopenia (42.6%), thrombocytopenia (46.6%), and elevation of aspartate aminotransferase (42.7%)Lymphopenia, features of low grade disseminated intravascular coagulation (thrombocytopenia, prolonged activated partial thromboplastin time, elevated D-Dimer), elevated alanine transaminases (ALT), lactate dehydrogenase (LDH) and creatinine kinase (CPK)Higher levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH), γ-glutamyl transpeptidase (γ-GT) and α-hydroxybutyric dehydrogenase (α-HBDH)
Language: English
Page range: 91 - 100
Submitted on: Jul 3, 2020
Accepted on: Nov 20, 2020
Published on: Feb 17, 2021
Published by: Hirszfeld Institute of Immunology and Experimental Therapy
In partnership with: Paradigm Publishing Services
Publication frequency: 1 times per year

© 2021 Arezoo Mirzaei, Sharareh Moghim, published by Hirszfeld Institute of Immunology and Experimental Therapy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.